We are live on ! Find out more
SAGE

Sage Therapeutics
SAGE

Delisted

SAGE was delisted on the 30th of July, 2025.

Back to rankings

176 hedge funds and large institutions have $278M invested in Sage Therapeutics in 2024 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 52 increasing their positions, 58 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more call options, than puts

Call options by funds: $2.74M | Put options by funds: $1.1M

4% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 24

1% more funds holding

Funds holding: 175 → 176 (+1)

0.5% less ownership

Funds ownership: 84.24% → 83.74% (-0.5%)

10% less repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 58

26% less capital invested

Capital invested by funds: $374M → $278M (-$95.5M)

Holders
176
Holders Change
+1
Holders Change %
+0.57%
% of All Funds
2.32%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
25
Increased
52
Reduced
58
Closed
24
Calls
$2.74M
Puts
$1.1M
Net Calls
+$1.64M
Net Calls Change
-$754K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$23.1M
2
CP
Caligan Partners
New York
+$18.7M
3
BFM
Boothbay Fund Management
New York
+$8.49M
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$3.9M
5
Federated Hermes
Federated Hermes
Pennsylvania
+$2.63M

Top Sellers

Rank Fund Capital Flow
1
RI
RTW Investments
New York
-$15.8M
2
State Street
State Street
Massachusetts
-$10.1M
3
PAI
Palo Alto Investors
California
-$7.3M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$7.06M
5
Vanguard Group
Vanguard Group
Pennsylvania
-$5.64M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of America
26
Bank of America
North Carolina
$1.72M -$2.17M -355,277 -53%
Hudson Bay Capital Management
27
Hudson Bay Capital Management
Connecticut
$1.34M -$599K -98,000 -28%
PP
28
PDT Partners
New York
$1.28M +$390K +63,804 +37%
Lazard Asset Management
29
Lazard Asset Management
New York
$1.21M +$1.36M +222,726 New
PA
30
Pinnacle Associates
New York
$1.2M +$316K +51,625 +31%
SFI
31
Susquehanna Fundamental Investments
Pennsylvania
$1.17M +$1.32M +215,871 New
JP Morgan Chase
32
JP Morgan Chase
New York
$985K +$187K +30,531 +20%
Bank of New York Mellon
33
Bank of New York Mellon
New York
$931K -$59K -9,655 -5%
Connor, Clark & Lunn Investment Management (CC&L)
34
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$918K +$633K +103,495 +158%
Verition Fund Management
35
Verition Fund Management
Connecticut
$918K +$199K +32,593 +24%
UBS Group
36
UBS Group
Switzerland
$884K -$27.8K -4,546 -3%
CSS
37
Cubist Systematic Strategies
Connecticut
$829K +$934K +152,726 New
HF
38
HRT Financial
New York
$818K -$130K -21,224 -12%
TI
39
Trexquant Investment
Connecticut
$786K -$190K -30,999 -18%
N
40
Nuveen
North Carolina
$775K – – –
ECM
41
ExodusPoint Capital Management
New York
$759K +$854K +139,748 New
Toronto Dominion Bank
42
Toronto Dominion Bank
Ontario, Canada
$742K +$836K +136,723 New
Two Sigma Investments
43
Two Sigma Investments
New York
$705K -$196K -32,046 -20%
Ameriprise
44
Ameriprise
Minnesota
$682K -$540K -88,350 -41%
Assenagon Asset Management
45
Assenagon Asset Management
Luxembourg
$656K -$399K -65,316 -35%
Two Sigma Advisers
46
Two Sigma Advisers
New York
$640K -$15.9K -2,600 -2%
DCM
47
DAFNA Capital Management
California
$588K – – –
American Century Companies
48
American Century Companies
Missouri
$580K -$1.38M -225,820 -68%
Barclays
49
Barclays
United Kingdom
$518K -$198K -32,341 -25%
Invesco
50
Invesco
Georgia
$502K +$28.3K +4,629 +5%
1
2
3 4 5

SAGE Hedge Fund Activity: Q4 2024 in Review

176 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q4 2024, worth a combined $278M — down 26% from $374M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new SAGE positions and 24 closed out — a net gain of 1 holder — while 52 added to existing stakes and 58 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $23.1M. The largest seller was RTW Investments, cutting an estimated $15.8M.

  • 176 institutional investors held Sage Therapeutics (SAGE) as of Q4 2024, up from 175 in Q3 2024.
  • Funds reported $278M of Sage Therapeutics stock for Q4 2024, down 26% quarter-over-quarter.
  • 25 funds opened new Sage Therapeutics positions in Q4 2024 and 24 closed out, a net change of +1 holder.
  • The largest Sage Therapeutics buyer in Q4 2024 was Morgan Stanley, an estimated $23.1M added.
  • The largest Sage Therapeutics seller in Q4 2024 was RTW Investments, an estimated $15.8M sold.

Based on aggregated 13F filings for Q4 2024.